Parameter
| Biomarker | circNF1 | Full name | Circular RNA Neurofibromin 1 | Molecular Type | Nucleic acid (circRNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis, and immunotherapy efficacy prediction | ||
| Disease | Esophageal Carcinoma | Disease Subtypes | / | ||
| Organ | Esophagus | Test Sample / Technology Platform | Organization/serum (ddPCR, qRT - PCR) | ||
| Pathobiological Mechanisms | Through the dual regulation of PD - L1 role: on one hand driven JAK induced by IL - 6 - STAT3 pathway activation of cancer, promote the combination of p - STAT3 and PD - L1 promoter; On the other hand, it binds to ANXA1 to block USP7-mediated deubiquitination of ANXA1, enhance the interaction between USP7 and PD-L1 and the stability of PD-L1, and finally promote tumor proliferation, metastasis and immune escape | ||||
| Clinical Availability Status | Clinical research phase: was validated in a number of clinical queue with the correlation, the efficacy of immunotherapy is potential immune treatment response prediction markers | ||||
| Notes and Dynamics | To provide new targets for ESCC immunotherapy, unite against PD - L1 treatment can significantly improve curative effect, is expected to enter the clinical practice | ||||